Investors, Press Releases
May 12, 2021
The Board of Directors approves the net financial position for the first quarter of 2021 in the amount of 104,668 thousand euro, and acknowledges the progress of the main clinical trials on Nidlegy™ and Fibromun in line with the expected timelines (Price Sensitive)